The CONSORT Statement—short for Consolidated Standards of Reporting Trials—is a reporting guideline for randomized controlled trials. It sets out the information needed to describe a trial’s rationale, design, conduct, analysis, and results transparently. Its principal tools are a checklist and a participant flow diagram, supported by explanatory guidance and extensions for particular trial designs or interventions. CONSORT concerns the completeness of reporting: adherence does not by itself establish that a trial was well designed, conducted without bias, or clinically important.
Purpose and scope
Randomized trials compare interventions by assigning participants, or groups of participants, to study arms through a random process. Their interpretation depends on details that a brief statement such as “participants were randomized” does not supply. Readers need to know how the allocation sequence was generated, whether upcoming assignments could be predicted, which outcomes were specified, and what happened to participants after allocation.
CONSORT makes these details explicit. It supports the appraisal of individual studies and the use of trial findings in systematic reviews, research synthesis, and evidence-based medicine. It applies to reports of randomized trials involving medicines, procedures, behavioral interventions, and other approaches, rather than only to pharmaceutical research.
The core framework principally addresses individually randomized, parallel-group trials. Other designs may require additional reporting elements. A clinical trial that is not randomized does not become a CONSORT trial simply because its authors complete the checklist.
Development and major revisions
The first CONSORT Statement appeared in 1996, bringing together earlier efforts to improve randomized-trial reporting. Revisions followed in 2001, 2010, and 2025.
CONSORT 2010 established a widely used 25-item checklist and a revised flow diagram. Its accompanying explanation-and-elaboration document explained the rationale for individual items and provided examples of informative reporting.
CONSORT 2025 updated the core framework to a 30-item checklist. It gives greater prominence to open-science practices, including access to registration information, protocols, statistical analysis plans, and information about data and code sharing. It also addresses patient and public involvement and incorporates updated expectations for reporting interventions, outcomes, and harms.
Checklist item counts refer to numbered items, several of which contain subitems. Consequently, a checklist’s total item count is not a count of every distinct reporting requirement. Version differences also matter when interpreting studies of CONSORT adherence.
Main reporting components
Trial identification and rationale
The title should identify the study as randomized, and the abstract should summarize its design, methods, principal findings, and conclusions accurately. The main report describes the scientific background, the reason for the trial, and its objectives.
Clear identification assists readers and database searches in distinguishing randomized evidence from observational research.
Design, participants, and interventions
A report describes the trial design, setting, eligibility criteria, and interventions in sufficient detail to understand what was compared. Relevant changes to the methods after the trial began should be reported with explanations.
Intervention descriptions include what was delivered, how and when it was delivered, and relevant details about the comparator. A comparator may be another active intervention, usual care, no intervention, or a placebo.
Randomization and masking
CONSORT distinguishes several processes that are sometimes incorrectly treated as interchangeable:
- Sequence generation: how the random allocation sequence was produced, including restrictions such as blocking or stratification.
- Allocation concealment: how upcoming assignments were kept hidden until participants were assigned.
- Implementation: who generated the sequence, enrolled participants, and assigned interventions.
- Blinding or masking: who remained unaware of assigned interventions after allocation and how this was achieved.
Allocation concealment protects the enrollment process against foreknowledge of assignments. Blinding addresses possible influences after allocation, such as differences in care or outcome assessment. Reporting one does not establish that the other occurred.
Outcomes and statistical analysis
Reports specify primary and secondary outcomes, their measurement, and assessment times. They also describe sample-size determination and the statistical methods used for comparisons.
Prespecified analyses should be distinguishable from analyses developed after examining the data. Important changes to outcomes or analyses require transparent reporting. The population included in each analysis, treatment of missing data, and handling of departures from assigned interventions must also be clear.
For example, merely labeling an analysis “intention-to-treat” does not explain which participants were included or how missing outcome measurements were handled.
Results, harms, and interpretation
Reports present participant characteristics, the numbers analyzed, results for each group, and estimates of between-group effects with measures of precision, such as confidence intervals. A significance test alone does not convey the size or uncertainty of an effect.
Reporting of harms includes how adverse outcomes were assessed and what was observed in each group. Information about patient safety is relevant even when efficacy is the trial’s main objective.
The discussion addresses limitations, potential sources of bias, applicability, and the balance of benefits and harms. Conclusions should reflect the reported findings rather than extending beyond the populations, interventions, or outcomes studied.
Participant flow diagram
The CONSORT flow diagram traces participants through the trial. Its main stages generally include:
- Enrollment: assessed for eligibility, excluded, and randomized.
- Allocation: assigned to each intervention and whether the assigned intervention was received.
- Follow-up: losses to follow-up and intervention discontinuations, with reasons.
- Analysis: numbers included in the analyses and exclusions, with reasons.
The diagram helps readers reconcile differences between the number randomized and the number contributing to particular analyses. Discontinuing treatment, withdrawing from follow-up, and being excluded from analysis are different events and should not be conflated.
Trials with complex designs may need adapted diagrams or additional tables.
Extensions and related guidelines
CONSORT extensions supply information that the core checklist alone cannot fully address. Examples cover cluster-randomized trials, crossover trials, noninferiority and equivalence trials, pragmatic trials, and pilot and feasibility trials. Other extensions address areas such as harms, abstracts, and nonpharmacological interventions.
Applicable extensions complement the core statement rather than replace it. Their publication dates may differ from that of the current core checklist.
CONSORT is also distinct from related reporting frameworks:
- SPIRIT addresses randomized-trial protocols, describing planned methods before results are available.
- PRISMA addresses systematic reviews.
- STROBE addresses observational studies.
These guidelines belong to the broader field of transparent research reporting, but they are not interchangeable.
Use and limitations
Journals may ask authors to submit a completed CONSORT checklist indicating where each item appears in a manuscript or associated material. Editors and peer reviewers can use it to identify omissions, while researchers conducting evidence syntheses can use the reported information to support appraisal.
CONSORT is not a trial-quality score, a substitute for a risk-of-bias assessment, or proof that reported methods were actually followed. A transparently reported trial may reveal serious methodological weaknesses; a poorly reported trial may leave its methods impossible to judge.
Similarly, registration and access to a protocol make comparisons between planned and reported methods possible, but do not themselves establish that deviations were inappropriate. CONSORT makes relevant decisions visible so that their implications can be assessed. It also does not replace ethics review, informed consent, or the responsibilities of an institutional review board.